Actinium Pharmaceuticals Revenue | ATNM

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Actinium Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000
90 K	-	81 K	1.03 M	1.14 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.14 M	81 K	586 K

Quarterly Revenue Actinium Pharmaceuticals

2026-Q2	2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
35 M	-	90 K	-	-	-	-	-	-	-	-	-	-	-	45 K	45 K	940 K	-	233 K	266 K	622 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
35 M	45 K	4.66 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
ADC Therapeutics SA ADCT	81.4 M	$ 1.31	6.5 %	$ 166 M	Schweiz
ADMA Biologics ADMA	510 M	$ 9.7	3.21 %	$ 2.31 B	USA
Adaptive Biotechnologies Corporation ADPT	277 M	$ 27.89	0.3 %	$ 4.23 B	USA
Arcturus Therapeutics Holdings ARCT	82 M	$ 13.3	1.06 %	$ 364 M	Israel
AbbVie ABBV	16.6 B	$ 265.08	0.02 %	$ 469 B	USA
Axsome Therapeutics AXSM	638 M	$ 193.45	0.24 %	$ 9.62 B	USA
Aytu BioScience AYTU	57.6 M	$ 2.28	2.24 %	$ 28.1 M	USA
Adagene ADAG	7.67 M	$ 2.97	0.62 %	$ 175 M	China
Abeona Therapeutics ABEO	5.82 M	$ 5.53	2.65 %	$ 293 M	USA
BioMarin Pharmaceutical BMRN	3.22 B	$ 62.21	0.06 %	$ 11.9 B	USA
Arbutus Biopharma Corporation ABUS	14.1 M	$ 4.85	0.2 %	$ 929 M	Canada
Can-Fite BioPharma Ltd. CANF	405 K	$ 2.16	0.45 %	$ 3.56 M	Israel
Achieve Life Sciences ACHV	5.06 M	$ 7.83	0.87 %	$ 341 M	USA
Catalyst Biosciences CBIO	117 M	$ 14.19	1.17 %	$ 1.27 B	USA
Amryt Pharma plc AMYT	223 M	-	-	$ 621 M	Britain
C4 Therapeutics CCCC	35.9 M	$ 3.08	0.3 %	$ 255 M	USA
Codexis CDXS	70.4 M	$ 1.38	0.72 %	$ 120 M	USA
Cerus Corporation CERS	234 M	$ 2.6	4.3 %	$ 496 M	USA
Coherus BioSciences CHRS	42.2 M	$ 1.26	1.48 %	$ 148 M	USA
Celldex Therapeutics CLDX	1.54 M	$ 31.12	0.28 %	$ 2.07 B	USA
CollPlant Biotechnologies Ltd. CLGN	2.37 M	$ 4.04	4.94 %	$ 49.3 M	Israel
AbCellera Biologics ABCL	75.1 M	$ 12.31	0.12 %	$ 3.68 B	Canada
Aclaris Therapeutics ACRS	7.83 M	$ 5.26	2.69 %	$ 645 M	USA
Фармсинтез LIFE	372 M	-	-	-	Russia
Clovis Oncology CLVS	36 M	-	-7.23 %	$ 13 M	USA
Cocrystal Pharma COCP	2.01 M	$ 1.19	1.26 %	$ 13.4 M	USA
Collegium Pharmaceutical COLL	205 M	$ 22.45	1.05 %	$ 711 M	USA
Corcept Therapeutics Incorporated CORT	761 M	$ 112.94	3.29 %	$ 11.7 B	USA
Crinetics Pharmaceuticals CRNX	7.7 M	$ 84.95	0.13 %	$ 7.99 B	USA
Corbus Pharmaceuticals Holdings CRBP	882 K	$ 7.74	0.19 %	$ 103 M	USA
Cardiff Oncology CRDF	593 K	$ 1.31	0.74 %	$ 87.6 M	USA
Curis CRIS	9.44 M	$ 0.95	0.98 %	$ 12.5 M	USA
CorMedix CRMD	312 M	$ 7.69	0.06 %	$ 554 K	USA
CRISPR Therapeutics AG CRSP	3.51 M	$ 55.76	1.2 %	$ 5.01 B	Schweiz
Concert Pharmaceuticals CNCE	32.6 M	-	-	$ 401 M	USA
Cue Biopharma CUE	27.5 M	$ 31.71	2.62 %	$ 3 B	USA
CEL-SCI Corporation CVM	255 K	$ 1.68	0.59 %	$ 13.5 M	USA
Cytokinetics, Incorporated CYTK	88 M	$ 65.81	0.04 %	$ 7.9 M	USA
Axon Enterprise AXON	2.78 B	$ 450.61	1.61 %	$ 35.2 B	USA
Brickell Biotech BBI	8.01 M	-	-5.38 %	$ 6.06 M	USA
DiaMedica Therapeutics DMAC	500 K	$ 7.56	7.16 %	$ 355 M	USA
Denali Therapeutics DNLI	331 M	$ 20.46	5.52 %	$ 3.53 B	USA
Precision BioSciences DTIL	34.3 M	$ 6.36	10.62 %	$ 81.6 M	USA
Dyadic International DYAI	3.09 M	$ 0.41	3.72 %	$ 14.8 M	USA
Editas Medicine EDIT	40.5 M	$ 2.69	0.17 %	$ 239 M	USA
Edesa Biotech EDSA	329 K	$ 3.97	1.46 %	$ 22.5 M	USA